Cipla Ltd. News and Updates

Name: Latest research reports of Cipla Ltd. authored by Deven Choksey and published by - Trendlyne research reports.
Item: Cipla Ltd.
Rating: 3
Author: Deven Choksey

Keep track of all breaking news on Cipla Ltd. from all sources in a single place.

Cipla Ltd.

08 Sep 2025

1565.00

0.40%

Growth outlook intact despite near-term headwinds

Hold: Cipla Ltd.

Deven Choksey

We have revised our FY26E/FY27E EPS estimates by +0.9%/-5.2%, as we factor in lower revenue on account of ramp down of Revlimid portfolio and ongoing price erosion in the US market, higher depreciation and amortization expense, offset by higher other income.

Cipla Ltd. is trading above all available SMAs

Cipla Ltd.

05 Sep 2025

1565.00

0.40%

Cipla launches Huena, India's first non-antibiotic drug to fight UTI

Business Standard

Drug firm Cipla on Friday said it has introduced a non-antibiotic treatment for patients suffering from recurrent urinary tract infections. The company has launched Methenamine Hippurate under the brand name HUENA. This marks a significant step forward for the company in its fight against anti-microbial resistance as it becomes the first to introduce such treatment in India, the Mumbai-based drugmaker said in a statement. Urinary tract infections (UTIs) are the second most common reason for antibiotic use in India, with infection cases doubling over the last 30 years. Women are more susceptible to UTIs, which account for 15 per cent of overall antibiotic prescriptions. Methenamine Hippurate offers an effective, non-antibiotic alternative for preventing UTIs by targeting bacteria in the bladder and urinary tract. Studies show it is as effective as long-term, low-dose antibiotic therapy for UTI prevention, with lower costs and no risk of antibiotic resistance. "We believe this...

Cipla Ltd. is trading above all available SMAs

Cipla Ltd.

02 Sep 2025

1565.00

0.40%

India, RoW biz to stay steady, US drug pipeline - the next trigger

Buy: Cipla Ltd.

Target

Sharekhan

Cipla has robust domestic and global product pipelines. US product pipeline to be healthy and will be key to driving growth from H2FY26E and contribute significantly from FY27E onwards.

Number of FII/FPI investors increased from 1114 to 1124 in Jun 2025 qtr.

Cipla Ltd.

27 Aug 2025

1565.00

0.40%

Cipla Recalls Over 20,000 Packs Of Inhalation Drug In US

NDTV Profit

The company is recalling 20,352 packs of the inhalation drug due to 'Failed Stability Specifications

Number of FII/FPI investors increased from 1114 to 1124 in Jun 2025 qtr.

Cipla recalls over 20k packs of inhalation drug in US

Business Line | 27 Aug 2025

Cipla Ltd.

22 Aug 2025

1565.00

0.40%

Five Stocks To Buy Today: Devyani, Cipla, IndusInd Bank And OthersCheck Target Price

NDTV Profit

The stock recommendations come with specific target price and stop loss price.

Cipla Ltd. has an average target of 1702.60 from 10 brokers.

Cipla Ltd.

22 Aug 2025

1565.00

0.40%

Looking for short-term F&O trade? Check this 'Bull Spread' on Cipla

Business Standard

Short term trend is positive as it is placed above its 5, 11 and 20 day EMA Stock price has broken out on the weekly chart with higher volumes

Cipla Ltd. has an average target of 1702.60 from 10 brokers.

Cipla Ltd.

29 Jul 2025

1565.00

0.40%

Stock to buy today: Cipla (1,571) BUY

Business Line

Cipla share price can rise to 1,650

Number of FII/FPI investors increased from 1114 to 1124 in Jun 2025 qtr.

Cipla shares rally 6% in 2 days as Q1 results impress; brokerages raise target up to Rs 1,875

Economic Times | 28 Jul 2025 2 more

Cipla Ltd.

28 Jul 2025

1565.00

0.40%

Result Update:Cipla

Buy: Cipla Ltd.

Axis Direct

We remain positive on the stock with a BUY rating and arrive at a target price of Rs 1,700 per share.

Cipla Ltd. has an average target of 1702.60 from 10 brokers.

Cipla Ltd.

27 Jul 2025

1565.00

0.40%

Next US fix could stanch Cipla's Revlimid bleed amid pricing pressure

Business Standard

Generics pipeline starts to pulse as Advair, Symbicort, and Abraxane prepare to hit the vein

Cipla Ltd. is trading above all available SMAs

Cipla Ltd.

27 Jul 2025

1565.00

0.40%

Cipla (CIPLA IN) Q1FY26 Result Update Strong US...

Buy: Cipla Ltd.

Prabhudas Lilladhar

CIPLA's Q1FY26 EBITDA (Rs17.8bn; 25.6% OPM) was 6% ahead of our estimates. Cipla managed to deliver strong margins during the quarter. During the quarter company witnessed price erosion for its generic products which was offset by new launches such as gAbraxane. Mgmt guided strong US revenues of $1bn for FY27 despite gRevlimid erosion. We expect Cipla to maintain its existing US sales run-rate. This will be aided by several high value niche launches in the US like gAbraxane, Nilotininb, gAdvair. Further, Cipla's...